AmyPore is a biotechnology company based around the leading science of Pr. Nouara Yahi (University of Aix-Marseillle) and Pr. Jacques Fantini (University of Aix-Marseille and Institut Universitaire de France). Their expertise in molecular neurosciences has led to the discovery of AmyP53, a first-in-class patented nontoxic molecule which tackles a common mechanism of neurotoxicity shared by Alzheimer and Parkinson diseases. The company applies its pioneering computational discovery platform coupled with high performance lipid-protein and protein-protein binding technology and ultrasensitive Ca2+ amyloid pore reporting assay to identify and neutralize novel targets that control pathologic protein misfolding. Created in 2018, AmyPore owns exclusive patent rights for the therapeutic use of AmyP53, including the development of a nasal spray for treating patients with Alzheimer or Parkinson diseases. Beyond AmyP53, AmyPore is developing a pipeline of therapeutic peptides able to prevent the formation of oligomers implicated in the development and progression of degenerative proteinopathies, including amyotrophic lateral sclerosis (ALS) and type 2 diabetes.